-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Glucocorticoids (GC) prescribed to treat chronic pediatric diseases are associated with osteoporotic fractures
Osteoporosis
Recently, a research article was published in the Journal of Clinical Endocrinology & Metabolism, an authoritative journal in the field of endocrine and metabolic diseases.
This multinational, randomized, double-blind, placebo-controlled Phase 3 trial (ClinicaTrials.
child
Changes in bone renewal markers in each group from baseline to the 12th month
The study recruited 34 children (mean age of 12.
Thus, in GIO children, compared with placebo, LSBMDZ increased significantly within one year after ZA treatment
Among GIO children, LSBMDZ increased significantly within one year after ZA treatment compared with placebo
Original source:
Leanne M Ward.
Zoledronic acid versus placebo in pediatric glucocorticoid- induced osteoporosis: A randomized double-blind phase 3 trial
in this message